Role of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis

被引:3
作者
Yin, Gaofei [1 ]
Guo, Wei [1 ]
Duan, Hanyuan [1 ]
Huang, Zhigang [1 ]
机构
[1] Capital Med Univ, Beijing Tongren Hosp, 1 Dongjiaomin Lane, Beijing 100730, Peoples R China
基金
中国国家自然科学基金;
关键词
HNSCC; meta-analysis; PD-1; PD-L1; inhibitors; systematic review; METASTATIC HEAD; OPEN-LABEL; RECURRENT; CANCER; PEMBROLIZUMAB; THERAPY;
D O I
10.1111/coa.13772
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background: The use of immunotherapy to treat recurrent/metastatic squamous cell carcinoma of the head and neck has become a popular research topic in recent years, and many clinical trials have been carried out. Objectives: To systematically evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma. Methods: We searched PubMed, Embase, Cochrane Library and other databases up to 1 November 2019 for publications reporting the use of PD-1/PD-L1 inhibitors in the treatment of squamous cell carcinoma of the head and neck. Revman 5.0 was used for combination analysis, and the overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and adverse events were determined. Results: Five articles were included. Compared with other treatment methods, this meta-analysis showed that treatment with PD-1/PD-L1 inhibitors can significantly improve OS (P < .0001), but there was no significant improvement in PFS or ORR. The risk of anaemia and nausea was significantly reduced by treatment with PD-1/PD-L1 inhibitors. Conclusions and Significance: Treatment with PD-1/PD-L1 inhibitors alone can improve the overall survival rate for recurrent/metastatic squamous cell carcinoma of the head and neck but there is no obvious advantage in other aspects and adverse events.
引用
收藏
页码:1013 / 1020
页数:8
相关论文
共 50 条
  • [31] Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis
    Zeng, Siyuan
    Liu, Daju
    Yu, Yongai
    Zou, Lei
    Jin, Xianyu
    Liu, Bing
    Liu, Lifeng
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [32] Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
    Chen, Shixue
    Zhang, Zhibo
    Zheng, Xuan
    Tao, Haitao
    Zhang, Sujie
    Ma, Junxun
    Liu, Zhefeng
    Wang, Jinliang
    Qian, Yuanyu
    Cui, Pengfei
    Huang, Di
    Huang, Ziwei
    Wu, Zhaozhen
    Hu, Yi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [33] Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis
    Liu, Xi
    Guo, Chang-Ying
    Tou, Fang-Fang
    Wen, Xiao-Ming
    Kuang, Yu-Kang
    Zhu, Qian
    Hu, Hao
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (01) : 116 - 127
  • [34] Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
    Yuwei Liu
    Jiahui Pan
    Fangbo Gao
    Wentao Xu
    Hongyu Li
    Xingshun Qi
    Advances in Therapy, 2023, 40 : 521 - 549
  • [35] PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma
    Mo, Dun-Chang
    Huang, Jian-Feng
    Luo, Peng-Hui
    Chen, Long
    Zou, Biao
    Wang, Han-Lei
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2023, 280 (01) : 1 - 9
  • [36] PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis
    Li, Jing
    Gu, Jian
    FUTURE ONCOLOGY, 2019, 15 (14) : 1667 - 1678
  • [37] Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors in the treatment of hepatocellular carcinoma: A meta-analysis and systematic review
    Zhang, Baoyan
    Su, Linfeng
    Lin, Yonghua
    ONCOLOGY LETTERS, 2024, 28 (01)
  • [38] A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer
    Fan, Zhongyuan
    Liang, Ye
    Yang, Xuecheng
    Li, Bin
    Cui, Lili
    Luo, Lei
    Jia, Yuefeng
    Wang, Yonghua
    Niu, Haitao
    ONCOTARGETS AND THERAPY, 2019, 12 : 1791 - 1801
  • [39] Efficacy and safety of PD-1/PD-L1 inhibitors combined with standard of care for locally advanced head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials
    Chen, Long
    He, Jin-Nian
    Zhao, Shi-Jie
    Peng, Li-Ping
    Mo, Dun-Chang
    Yin, Shi-Hua
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 209
  • [40] Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC)
    Abulizi, Adila
    Yan, Guangpeng
    Xu, Qian
    Muhetaer, Reyihanguli
    Wu, Shihan
    Abudukelimu, Kudelaiti
    Chen, Xi
    Liu, Chengjiang
    Li, Jun
    SCIENTIFIC REPORTS, 2024, 14 (01):